Business Description
AIM ImmunoTech Inc
NAICS : 325414
SIC : 2836
ISIN : US42366C3016
Description
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 18.2 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -32.78 | |||||
| Beneish M-Score | -7.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -7.2 | |||||
| 3-Year EBITDA Growth Rate | -16.9 | |||||
| 3-Year EPS without NRI Growth Rate | -10.1 | |||||
| 3-Year FCF Growth Rate | -9.4 | |||||
| 3-Year Book Growth Rate | -48.7 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.34 | |||||
| 9-Day RSI | 35.67 | |||||
| 14-Day RSI | 41.64 | |||||
| 6-1 Month Momentum % | 4.51 | |||||
| 12-1 Month Momentum % | -10.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.68 | |||||
| Quick Ratio | 1.68 | |||||
| Cash Ratio | 1.51 | |||||
| Days Sales Outstanding | 1590.1 | |||||
| Days Payable | 22112.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.2 | |||||
| Shareholder Yield % | -2.77 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.21 | |||||
| Operating Margin % | -15800.5 | |||||
| Net Margin % | -14337.62 | |||||
| FCF Margin % | -10528.22 | |||||
| ROE % | -106.14 | |||||
| ROA % | -91.19 | |||||
| ROIC % | -616.3 | |||||
| ROC (Joel Greenblatt) % | -2535.98 | |||||
| ROCE % | -112.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 101.63 | |||||
| PB Ratio | 2.1 | |||||
| Price-to-Tangible-Book | 2.77 | |||||
| EV-to-EBIT | -0.29 | |||||
| EV-to-EBITDA | -0.29 | |||||
| EV-to-Revenue | 44.4 | |||||
| EV-to-Forward-Revenue | 3.64 | |||||
| EV-to-FCF | -0.42 | |||||
| Price-to-Median-PS-Value | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 4.07 | |||||
| Price-to-Net-Cash | 5.08 | |||||
| Earnings Yield (Greenblatt) % | -344.83 | |||||
| FCF Yield % | -103.08 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers